IMPORTANCE Molecular alterations in lichen sclerosus-associated vulvar squamous cell carcinoma (LS-VSCC) are largely unknown.
V ulvar squamous cell carcinoma (VSCC) represents 5% of all female genital cancers. 1 Up to 80% of all VSCCs arises in a background of inflammatory vulvar dermatosis, typically lichen sclerosus (LS). 2, 3 The molecular alterations involved in onset and/or progression of LS-associated VSCC (LS-VSCC) are largely unknown.
The RARβ gene is a tumor suppressor gene encoding retinoic acid receptor β (RARβ), a member of nuclear receptor superfamily. 4 The RARβ protein binds retinoic acid, the biologically active form of vitamin A, which mediates cellular signaling in embryonic morphogenesis, cell growth, and differentiation. 4 Loss of RARβ activity, especially through gene promoter methylation, has been observed in different types of cancers. [5] [6] [7] The tumor suppressor function of RARβ depends on down-regulatory activity of activator protein-1 (AP-1), a transcription factor composed of proto-oncoproteins c-Jun and c-Fos, which is a positive regulator of cell proliferation. 8 The aim of this study was to investigate the role of the RARβ gene in onset/progression of LS-VSCC. Therefore, levels of mRNA expression and promoter methylation of RARβ were assessed in pathologic specimens including LS-VSCC, cancerassociated vulvar LS, cancer-free vulvar LS, and in normal skin specimens. In addition, the expression level of the c-Jun gene and its relationship with RARβ expression were investigated.
Methods
Tissue samples were from University-Hospital of Ferrara, Ferrara, Italy. They included: (1) 20 formalin-fixed and paraffin-embedded VSCC specimens adjacent to LS (LS-VSCC) (HPV-negative); (2) 20 cancer-associated VLS (caVLS) formalin-fixed and paraffinembedded specimens adjacent to VSCC; (3) 20 cancer-free VLS (cfVLS) fresh specimens obtained from diagnostic biopsies; (4) 20 normal fresh skin specimens obtained from women surgically treated for nonmalignant skin lesions. The study was approved by the University-Hospital of Ferrara institutional review board. Patients provided their written informed consent. DNA/ RNA from formalin-fixed and paraffin-embedded and fresh tissue specimens were extracted as described.
9,10
Participant DNA was treated with sodium bisulfite using Epitect Bisulfite kit (Qiagen). 9 Methylation was assayed at the RARβ promoter (OMIM: 180220) by sequencing the PCR-amplified bisulfite-treated DNA using the automated ABI-Prism-3130X DNA sequencer (Applied). 9 The RARβ promoter region studied contained 9 CpGs within a polymerase chain reaction (PCR) amplicon of 86 bp.
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The RNA was reverse transcribed with random primers using RNA-to-cDNA Kit (Roche). RARβ and c-Jun messenger RNA (mRNA) expressions were analyzed with the ABI7500 fast real-time PCR system (Thermofisher) using Power SYBR Green PCR Master Mix (Sigma-Aldrich).
8,12,13 The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as an internal control. A series of quantitative reverse transcription PCR (RT-qPCR) assays were performed 3 times, each with 3 repeated measures. Data analysis was performed with the 2 −ΔΔCt method.
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The χ 2 trend test with Yate's correction was used to compare the observed RARβ epigenotypes among LS-VSCC, caVLS, cfVLS, and normal skin specimens. Statistical analyses were carried out with GraphPad Prism for Windows (version 5.0, GraphPad). P < .05 was considered statistically significant.
Results

Analysis of RARβ mRNA Expression
In LS-VSCC specimens, RARβ mRNA results were 3.4-fold and 3.6-fold downregulated compared with caVLS (P = .001) and cfVLS (P = .005), respectively, and 4.8-fold downregulated compared with normal skin specimens (P < .001) ( Figure 1 ). In caVLS 
Key Points
Question Is the retinoic acid receptor β (RARβ) tumor-suppressor gene involved in the onset and/or progression of lichen sclerosus-associated vulvar squamous cell carcinoma (LS-VSCC)?
Findings In this case-control study of 80 tissue specimens, RARβ expression was strongly downregulated by promoter methylation in LS-VSCC. The degree of promoter methylation correlated with the severity of LS-VSCC: full promoter methylation of RARβ was associated with LS-VSCC among patients with lymph nodes metastasis at diagnosis who subsequently experienced recurrence.
Meaning RARβ dysregulation may play a role in the tumorigenic process of LS-VSCC and promoter methylation of RARβ may be used as a clinical prognostic marker in patients with LS-VSCC.
and cfVLS specimens, the RARβ mRNA expression results were statistically similar to those in normal skin specimens.
RARβ Promoter Methylation Analysis
To investigate whether RARβ gene expression might be modified by its promoter methylation, the methylation status of the RARβ promoter region was investigated by sequencing analysis of the RARβ-PCR amplicons in specimens. RARβ hypermethylated amplicons, ie, amplicons showing 50% or more methylated CpG dinucleotides, were taken into account in this analysis. Overall, RARβ hypermethylation was detected in 18 of 20 (90%) LS-VSCC specimens, 10 of 20 (50%) caVLS, 11 of 20 (55%) cfVLS, and 5 of 20 (25%) normal skin specimens. The differences in RARβ hypermethylation between LS-VSCC (P = .02) and caVLS (P = .03), cfVLS, and normal skin specimens were statistically significant (P < .001) (Figure 2) . The degree of methylation of RARβ promoter was higher in LS-VSCC, ranging from 5 to 9 (full promoter methylation) CpGs methylated, than in caVLS, cfVLS and normal skin specimens, which was up to 5 CpGs methylated. No differences in RARβ promoter hypermethylation frequencies were assessed among caVLS, cfVLS, and normal skin groups (P > .05). Figure 2D shows the clinical course of LS-VSCC patients according to their degree of hypermethylation.
Analysis of c-Jun mRNA Expression
Expression of c-Jun mRNA was measured by RT-qPCR in the same specimens analyzed for RARβ mRNA expression. In LS-VSCC c-Jun mRNA was increased by 4.3-fold and 1.4-fold compared with caVLS (P < .001) and cfVLS (P = .001), respectively, and by 2.6-fold compared with normal skin specimens (P < .001) (Figure 3) . In cfVLS and caVLS specimens, the c-Jun mRNA expression was statistically similar to that in normal skin specimens.
Number of methylated dinucleotides in
Discussion
To date, few reports have addressed the epigenetic alterations involved in VSCC. Hypermethylation of some genes has been described in VSCC, associated or not with LS, indicating that aberrant promoter methylation is a common event in VSCC. 2, 10, 14 Moreover, some gene promoters have been found to be methylated in progression from VLS to VSCC, suggesting that such epigenetic deregulations are early events affecting VLS. 2, 10, 14 In this study, RARβ gene promoter was found to be strongly methylated and consequently downexpressed in LS-VSCC compared with caVLS, cfVLS, and normal skin, indicating that RARβ dysregulation may play a role in the etiopathogenesis of LS-VSCC. In contrast, RARβ promoter methylation and gene expression were found to be at similar levels in caVLS, cfVLS, and normal skin, indicating that RARβ methylation is a specific risk factor in development of LS-VSCC. These data are in agreement with other studies reporting methylation-induced RARβ downexpression in different carcinomas. 5, 6 To our knowledge, this is the first report on the hypermethylation of RARβ gene in LS-VSCC. We found that RARβ promoter showed different degrees of methylation, ranging from 5 to 9 CpGs methylated, in LS-VSCC. importantly, none of the LS-VSCC with 5 to 6 CpGs methylated, and 5 of 8 (63%) LS-VSCC with 7 to 8 CpGs methylated were from patients with lymph node metastases at diagnosis, respectively. Of note, 2 of 2 (100%) LS-VSCC with 9 of 9 CpGs methylated were from patients with lymph node metastases at diagnosis and subsequent recurrence. These data indicate an association between degree of methylation of RARβ and clinical course, and suggest that promoter methylation status may be a prognostic factor in patients with LS-VSCC.
It is well known that cancer develops in a stepwise manner through inactivation of tumor suppressor genes and activation of oncogenes. In this study, mRNA levels of c-Jun tested higher in LS-VSCC than in caVLS, cfVLS, and normal skin, underscoring a cross-link between the RARβ tumor suppressor gene and the c-Jun oncogene. Overexpression of c-Jun has been found in several human cancers, 15 
Limitations
The limitation of this study is the small sample size of specimens analyzed.
Conclusions
Results of this study indicate that the RARβ gene is hypermethylated and consequently downexpressed in LS-VSCC, and that there is an inverse correlation between RARβ expression and c-Jun expression, indicating that RARβ gene dysregulation may play a role in the tumorigenic multiphase process of LS-VSCC. We also show that the degree of methylation of RARβ promoter correlates with the clinical course in patients with LS-VSCC. Therefore, RARβ promoter methylation status may be used as a prognostic factor in clinical treatment of patients with LS-VSCC.
